Navigation Links
Rate of chronic health problems for low-birth-weight children does not increase in adolescence
Date:7/27/2011

In a follow-up of extremely low-birth-weight children, the rates of chronic health conditions overall, and asthma specifically, did not change between the ages of 8 and 14 years, although the rate of obesity did increase, according to a study in the July 27 issue of JAMA.

Changes in perinatal care in the 1990s resulted in improved survival among extremely low-birth-weight (ELBW) infants (weight less than 2.2 lbs.).

"The school-aged outcomes for these children indicate very high rates of chronic health conditions and developmental problems compared with normal-birth-weight (NBW) controls. There have been few reports of the outcomes of ELBW children during adolescence, which is a time of enormous social, health, and developmental change," according to background information in the article.

Maureen Hack, M.B., Ch.B., of University Hospitals Rainbow Babies & Children's Hospital and Case Western Reserve University School of Medicine, and colleagues conducted a study to examine changes in the rates of chronic conditions of ELBW children between the ages of 8 and 14 years. In a previous study, the authors reported that compared with NBW controls, ELBW children at 8 years of age had significantly higher rates of chronic conditions, functional limitations, and special health care needs. The current study, conducted from 2004 through 2009, included 181 ELBW children from the previous study and 115 NBW controls of similar sociodemographic status, born from 1992 through 1995.

Within the ELBW group, the overall rates of chronic conditions did not change between the ages of 8 and 14 years (75 percent and 74 percent, respectively) but there was a significant decrease in the average number of chronic conditions per child. On measures of functional limitation, the rates decreased significantly from 56 percent to 46 percent. In a comparison of the groups, the significantly higher rates and numbers of chronic conditions among the ELBW children at age 8 years persisted at age 14 years (74 percent for ELBW children vs. 47 percent for NBW controls).

"At age 14 years, 46 percent of ELBW children had functional limitations compared with 16 percent of NBW controls, including mental or emotional delay, trouble understanding simple instructions, and speaking and communicating," the authors write.

The rate of ELBW children with asthma requiring medication did not change between the ages of 8 and 14 years (23 percent at both ages), while for the NBW controls, the rate of asthma increased significantly between the ages of 8 and 14 years, from 8 percent to 17 percent, respectively. Differences in rates of asthma between ELBW and NBW children were no longer significant at the age of 14 years (23 percent vs. 17 percent, respectively).

The rate of obesity in ELBW children increased from 12 percent at age 8 years to 19 percent at age 14 years. This rate did not change among the NBW controls; at age 14 years, the rate of obesity did not differ significantly between the ELBW children and NBW controls.

"Our results may have relevance to current survivors. The ELBW status may be considered a marker for the risk of multiple chronic conditions that warrant closer than average health surveillance during adolescence. In addition to therapy for neurodevelopmental disorders, ELBW children with asthma or obesity should receive interventions such as smoking prevention and exercise encouragement to reduce the consequences of these conditions and to possibly enhance their long-term adult outcomes," the authors conclude.


'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. Vitamin E shows possible promise in easing chronic inflammation
2. New research lights up chronic bacterial infection inside bone
3. When acute hepatitis develops into chronic hepatitis
4. Research uncovers promising target to treat chronic abdominal pain
5. New trigger for chronic inflammation in rheumatoid arthritis discovered
6. Early-life experience linked to chronic diseases later in life: UBC research
7. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
8. New potential to treat chronic obstructive pulmonary disease
9. Higher opioid dose linked to overdose risk in chronic pain patients
10. Discovery of new type of immune cells regulating inflammation in chronic diseases
11. New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):
(Date:12/4/2016)... ... 03, 2016 , ... Microbial genomics leader uBiome is awarding ... been made to Dr. Renato Polimanti of Yale University School of Medicine, who ... Grant proposals have been vetted by the company’s scientific review committee. , ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
Breaking Biology Technology: